Kornimate/medical-research-clean huggingface dataset:
female muscle enhancement

Conditions: Muscle Function

Summary: participating in regular physical activity has been shown to reduce the risk of developing some diseases and disabilities that can occur with ageing. muscles naturally decline with age, and in females this appears to occur more so around the time of menopause. time, work, family commitments and the availability of facilities have all been identified as barriers to exercise in middle age. increasing activity levels in middle age appears to improve muscle function and bone health. however, there is a lack of evidence in how muscle function responds to low impact resistance exercise in middle aged females. this study aims to assess the effectiveness and the mechanisms associated with building muscle as well as the effect on quality of life in middle aged (40-60 years) females using a low impact resistance training programme.


Eligibility criteria:
inclusion criteria: * females aged 40-60 years of age at time of screening. * body mass index \ 18.5kg/m2 * considered moderately active according to the 7 day international physical activity questionnaire (ipaq) (craig et al., 2003) * self-reported as healthy (absence of injury or disease). * availability and willingness to attended 12 weeks of exercises classes 4-5 times per week at st luke's campus exeter and participate in the study lasting a total of 26 weeks. exclusion criteria: * pregnant, lactating or planning a pregnancy. * current diagnosis of a chronic disease such as diabetes, autoimmune disease, cardiovascular disease, kidney disease. * hysterectomy and/or ovariectomy. * currently prescribed hormone replacement therapy. * hypertension (bp ≥149/90 mm/hg) * either current smoker, or history of smoking in the past 6 months. * currently taking supplements that have been shown to impact muscle function and muscle mass, such as creatine, in the last 6 months. * prescribed medications that have been shown to impact muscle function and muscle mass, such as steroids, in the last 6 months. * history of epilepsy. * current or recent injury within the last 6 months that may affect their ability to carry out the resistance training program. * advised not to exercise by their general practitioner or medical professional. * resistance training consistently for 3 or more times per week for the last 2 months

Keywords: muscle function females resistance exercise
efficacy trial of oral tetrahydrocannabinol in patients with fibromyalgia

Conditions: Fibromyalgia

Summary: the objective of the study is to evaluate the effectiveness of oral tetrahydrocannabinol in patients suffering from fibromyalgia


Eligibility criteria:
inclusion criteria: - adult (\>18y.o) patient with fibromyalgia, diagnosed by acr criteria exclusion criteria: - children \< 18 years old patients with following psychiatric disorders: * psychosis or history of acute psychosis * schizophrenia * bipolar disorder patients smoking marijuana, using hashish or any other form of cannabis. patients with history of drug abuse or illicit drug use patients receiving chronic treatment with strong opioids (morphine, oxycodone, fentanyl, methadone, hydromorphone, buprenorphine, pethidine). weak opioids as tramadol or propoxyphene will be allowed. pregnant patients

Keywords: fibromyalgia tetrahydrocannabinol chronic widespread pain
effect of closed kinetic chain on hip stability in spastic cerebral palsy post selective dorsal rhizotomy

Conditions: Cerebral Palsy; Selective Dorsal Rhizotomy

Summary: purpose of the study: to evaluate the effect of closed kinetic chain on hip stability after selective dorsal rhizotomy on spastic cerebral palsy.

* this is a prospective randomized controlled clinical trial, conducted at kafr el sheikh hospital. * sixty-six children of both genders. * the study will include children (age 5-14years) post selective dorsal rhizotomy. * children meeting the inclusion criteria will be randomly assigned to one of two groups: * experimental group: children in this group will receive closed kinetic chain. * control group: patients in this group will receive traditional physical therapy. * randomization will be achieved using computer-generated random numbers to ensure an equal distribution of patients between the two groups.

Eligibility criteria:
inclusion criteria: * 1-patients will be aged from 5 to 14 years 2- will be included both genders post selective dorsal rhizotomy. 3- the gmfcs level i-ii spastic diplegia, able to stand up from a chair independently and maintain standing for more than 5 seconds without falling. 4- had not received any strength training program in the past 3 months before the study. 5- able to attend physical therapy (pt) treatment at least three a week before and during this study. exclusion criteria: * 1-have perceptual, cognitive, visual and auditory disorder. 2- botulinum toxin injection to the lower extremities within 6 months. 3- medical conditions that prevented children from participating in the exercises. 4- previous lower extremity surgery, such as prior hamstring muscle lengthening. 5- existence of any orthopedic condition or any static hip, knee or ankle deformities.
neoadjuvant tislelizumab plus chemotherapy for resectable locally-advanced head and neck squamous cell carcinoma

Conditions: Head and Neck Squamous Cell Carcinomas; Resectable Head and Neck Squamous-cell Carcinoma

Summary: for resectable squamous cell carcinoma of the head and neck , novel therapeutic approaches are still needed to improve outcomes. neoadjuvant immunochemotherapy is considered as a potentially effective strategy. the purpose of this study is to evaluate the safety and efficacy of neoadjuvant of tislelizumab combined with platinum doublet for resectable locally-advanced head and neck squamous-cell carcinoma .


Eligibility criteria:
inclusion criteria: 1. patients who voluntarily participate in the project and sign the informed consent. 2. be 18 years of age on day of signing informed consent. 3. the performance status of the eastern cooperative oncology group (ecog) is 0-1. 4. according to the 8th edition of the guidelines of the american joint committee on cancer (ajcc), patients with stage iii-iva tumors confirmed by pathology as head and neck squamous cell carcinoma. 5. resectable tumors were evaluated by head and neck surgeons before enrollment to exclude clinical evidence of distant metastasis. 6. demonstrate adequate organ function. exclusion criteria: 1. the patient has abnormal blood indicators, abnormal liver and kidney function. 2. the patient has received prior systemic anti-cancer therapy for head and neck squamous cell carcinoma including investigational agents within 3 months of first dose of study treatment. 3. the patient has previously suffered from other tumors , or has previously undergone anti-tumor treatments such as surgery, chemotherapy, and radiotherapy within the past 5 years. 4. the entire clinical research process cannot be completed due to personal, social and economic reasons. 5. serious systemic diseases in the past and the diseases cannot be cured or controlled by drugs .
prostate cancer utilities and cost-effectiveness analysis

Conditions: Prostate Cancer

Summary: the purpose of this study is to help doctors and patients make better decisions about prostate cancer treatment. this research is being done because we do not know how patient preferences for health states related to prostate cancer affect the final treatment decision.

the goal of this project is to incorporate patients' preferences into a previously developed prostate cancer treatment decision-model and to understand the implications for doing so for cost-effectiveness analysis. to do this, it is first necessary to obtain patient utility scores (i.e., patient preference weights). to do this we will perform a survey of patients visiting the urology clinic to undergo prostate biopsies to validate a method of utility assessment, and understand the patients' individual evaluations of treatment-related health studies. we will also ask patients questions relating to their anxiety levels concerning the possible diagnosis of prostate cancer.

Eligibility criteria:
inclusion criteria: * patients undergoing prostate biopsy exclusion criteria: * women and children will be excluded, as prostate cancer occurs in men only * diagnosis of dementia

Keywords: prostate cancer cost-effectiveness analysis utility assessment
study of medi 507 in the treatment of pediatric patients

Conditions: Graft Versus Host Disease

Summary: to assess the safety of escalating dose levels of medi-507 in pediatric stem cell and bone marrow allograft recipients who have at least grade ii gvhd.

this is a phase i, open-label dose escalation trial of medi-507 in pediatric sct and bmt recipients with at least grade ii acute gvhd. all patients will receive steroid therapy and medi-507 for treatment of gvhd

Eligibility criteria:
inclusion criteria: * allogeneic bmt or sct recipients * acute gvhd of at least grade ii severity * age 2 to 17 years * evidence of engraftment (anc over 500 cells/mm3 on two consecutive days within seven days before study entry) * receipt of gvhd prophylaxis regimen including methotrexate, tacrolimus or cyclosporine * receipt of at least 2 mg/kg of methylprednisolone (or equivalent corticosteroid) between eight and 24 hours prior to the first medi-507 dose for gvhd treatment * both males and females are eligible, but sexually active females at risk of pregnancy of childbearing potential must agree to use an effective method of avoiding pregnancy (which includes oral or implanted contraceptives, iud, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner) beginning 30 days before the first study infusion and continuing through 60 days after the final study infusion. exclusion criteria: * treatment of acute gvhd with methylprednisolone (or equivalent corticosteroid) at a total dose exceeding 14 mg/kg (or equivalent) over a seven day period (for example, 2 mg/kg/day for seven days) * previous receipt of medi 507 * previous treatment with any anti-t cell monoclonal antibodies, such as okt3, daclizumab (zenapax), or basiliximab (simulect) * treatment with anti-thymocyte globulin (atg, atgam or others) within 14 days * more than one allogeneic bone marrow or hematopoietic stem cell allograft * use of other investigational agents within 30 days (this does not include the use of licensed agents for indications not listed in the package insert) or current participation in a research protocol in which an investigational agent was administered * any of the following clinical settings or diagnoses: * documented or presumed significant active infection * pregnancy or nursing mother * evidence of infection with hiv-1, hepatitis b or c virus * hemodialysis or chronic peritoneal dialysis * use of a ventilator * chronic gvhd * active veno-occlusive disease of the liver * moribund patient

Keywords: acute gvhd of at least grade ii severity
sars-cov-2/covid-19 infection among health care workers

Conditions: SARS-CoV-2; BCG; Health Care Worker; COVID-19

Summary: the present study finds opportunities and justifications, taking into consideration that the nature of professional practice in health needs scientific evidence resulting from systematic and systemic studies to strengthen the basis for the decisions made to have an impact on various levels, from the patient to health management itself. in addition, cabo verdean authorities may benefit from new evidence obtained by this study. it intends, in a growing number of health professionals exposed or infected with sars-cov-2, in the different health structures of the country, to contribute to substantiate a better perception of the problem and the required solutions. therefore, assessing the potential risk factors for sars-cov-2 infection among healthcare workers will be essential to characterize virus transmission, preventing future infections in them and providing the associated healthcare. due to the advances and important changes described, questions arise that guide this research and allow us to identify the problem.

the problem is stated in the following starting questions: what conditions and factors are associated with infection and non-infection by sars-cov-2 among health professionals working in the three hospitals on the islands of santiago and são vicente? which are they (gender, age group, profession, type of contact, etc.)? where do the infected hcw typically work (sector)? when and how did the infection occur? what is the prevalence of sars-cov-2 antibody in professionals with confirmed sars-cov-2 infection and in hcw that thought they were not infected by sars-cov-2? how long do anti-sars-cov-2 antibodies last? what is the impact of infection on unplanned absenteeism? which symptoms and complaints (if any) persists after sars-cov-2 infection?

Eligibility criteria:
inclusion criteria: * being a healthcare professional working in one of the hospitals where the study will take place * be aged ≥18 years; * cases: sars-cov-2 infection confirmed by pcr test and/or rapid antigen test; * control: no evidence and/or record of past infection with sars-cov-2. exclusion criteria: * case: confirmation of diagnosis test for sars-cov-2 without indication of specimen collection date. * control: suspected sars-cov-2 infection.
cinnamon and withania on weight loss

Conditions: Obesity

Summary: with the prevalence of obesity soaring and the absence of an effective and safe treatment that is low-cost and always feasible, the use of food supplements has gained attention for the potential benefits in the absence of significant safety concerns. cinnamon (cc) and withania somnifera (ws) are plant-based supplements reported to be effective in improving metabolic health and body composition, the first mainly acting on insulin resistance and the second on energy expenditure and leptin resistance, as shown in preclinical and some clinical studies. their association, possibly synergistic leveraging different mechanisms of action, has never been studied. this was a double-blind placebo-controlled study. patients with overweight or obesity were prescribed a mildly hypocaloric diet with cc 300 mg plus ws 150 mg tid for 4 weeks in a cross over design and anthropometric parameters together with safety outcomes were collected.


Eligibility criteria:
inclusion criteria: * age range: 25-75 years * overweight or obesity (bmi range: 26-35) exclusion criteria: * heart failure * congenital cardiomyopathies * episodes of tachy/brady-arrythmias * acute myocardial infarction within 3 months from the enrollment * inability or unwillingness to provide informed consent * pregnancy
a study of clinical outcomes in patients with relapsed/refractory multiple myeloma (rrmm) treated with t-cell redirectors outside of clinical trials

Conditions: Relapsed/Refractory Multiple Myeloma (RRMM)

Summary: the purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with rrmm outside of clinical trials.


Eligibility criteria:
inclusion criteria: * have a documented diagnosis of multiple myeloma * received the first dose of teclistamab on or before 31 december 2022, regardless of the duration of teclistamab treatment (realitec cohort 1) or received the first dose of teclistamab from 01 january 2023 to 31 december 2024, inclusive, regardless of the duration of teclistamab treatment (realitec cohort 2) or received the first dose of talquetamab on or before 31 december 2023, regardless of the duration of talquetamab treatment (realital cohort). participants who received both teclistamab \& talquetamab can be included in both realitec and realital cohorts * received at least one dose of teclistamab/talquetamab * provision of a patient-signed informed consent form (icf), or an icf waiver for deceased patients as applicable based on country/site-specific requirements exclusion criteria: * to be excluded from realitec cohorts if received teclistamab as part of an interventional clinical trial * to be excluded from realital cohort if received talquetamab as part of an interventional clinical trial * participants who have received teclistamab as part of a janssen pre-approval access program are excluded from the realitec cohort 2
evaluation of the effects of the product rv5075a-mf6793 in diabetic patients presenting foot xerosis and superficial fissures, an exploratory study.

Conditions: Diabetic Foot Xerosis

Summary: this exploratory study is meant to assess the efficacy of a product in diabetic patients presenting foot xerosis and superficial fissures this exploratory study will be conducted as randomized, comparative study in parallel groups. in order to perform this clinical study, 60 female/male subjects, aged between 18 and 75 years old, with controlled type 1 or 2 diabetes and presenting foot xerosis and superficial fissures, are enrolled. the subjects are randomly divided in two groups, (group i or group ii), where one group applies the test product and another group applies comparative product. the subjects apply the investigational/comparator products to both feet, twice a day, in the mornings and evenings, for 28 consecutive days. 3 visits are planned : * visit 1: inclusion (d1) * visit 2: intermediate visit (d5 ±2) * visit 3: end-of-study visit (d28 ±2)


Eligibility criteria:
main inclusion criteria: * gender: male/female; * age: 18 to 75 years old; * presenting skin phototype between i and iv according to the fitzpatrick phototyping scale; * presenting controlled type 1 or 2 diabetes; * presenting xerosis intensity on feet is rated as 6 according to the xerosis assessment scale (xas). main non-inclusion criteria: * subject with uncontrolled diabetes and/or with diabetes complications * subjects with any foot condition or medical history liable to interfere with the evaluation of the efficacy or cutaneous tolerance of the investigational products according to the investigator's assessment * topical or oral treatment established or modified during the previous weeks or planned to be established or modified during the study, liable to interfere with the evaluation of the efficacy or cutaneous tolerance of the investigational products according to the investigator's assessment
evaluation of three irrigants, sodium hypochlorite, chlorhexidine and combination of chx+h2o2 in endodontic treatment.

Conditions: Periapical Periodontitis

Summary: this study will evaluate the synergistic effect of chx + h2o2 when used as an irrigant during biomechanical preparation.in root canal treatment on periapical healing and compared with chlorhexidine( chx) and sodium hypochlorite (naocl).

after a thorough history, clinical and radiographic examination with all eligibility confirmation, written informed consent will be taken from the patient after explaining the procedure and its associated risks and benefits. patients randomly allocated to one of the three study groups sodium hypochlorite (naocl), chlorhexidine (chx) and combination of (chx+h2o2). all three irrigants will be used according to standard protocol during biomechanical preparation. pain analysis will be carried out preoperatively and postoperatively at every 6 hours for 1 day and then every 24 hours till 7 days after the intervention. all the subjects will be followed up for evaluation of clinical and radiographic success at 3, 6 months and 1year.

Eligibility criteria:
inclusion criteria: * all patients over 18 years of age. * mature permanent mandibular molars. * a radiographic evidence of periapical radiolucency (minimum size \> 2mm×2mm) and a diagnosis of pulpal necrosis, as confirmed by the negative response to cold and electrical tests; and absence of bleeding on entering the pulp chamber. exclusion criteria * diabetics, immunocompromised patients, pregnant females, any systemic disease. * patients with a history of analgesic intake within the past 3 days and antibiotics in the last month. * patients with pockets ≥ 4mm or having marginal or furcal bone loss due to periodontitis. * non-restorable tooth, fractured, perforated roots and inflammatory root resorption. * teeth those are not suitable for rubber dam isolation. * primary teeth.

Keywords: sodium hypochlorite chlorhexidine hydrogen peroxide
effects of tens and interference on pain, functional status and range of motion in shoulder pain in stroke patients

Conditions: Hemiplegic Shoulder Pain

Summary: effects of tens and interference on pain, functional status and range of motion in shoulder pain in stroke patients

hemiplegic shoulder pain treatment methods are, analgesics, local steroid injection, physical therapy modalities and exercise. there are publications about the use of tens and interferential currents (ifc) in the treatment of hemiplegia related shoulder pain and their effectiveness. however when we look at the literature, we did not find a study that evaluated the efficacy of tens and ifc in hemiplegic shoulder pain. for this reason, in this study, we aimed to determine the effects of these analgesic treatment modalities on the patient's pain, functional status and shoulder range of motion (rom) in these patients. 60 stroke patients with shoulder pain randomized to four treatment groups. 15 patients in group 1 were given tens treatment to the shoulder area for 25 minutes by conventional method ( 20 sessions, 5 times a week), then, a classical stroke rehabilitation program was applied under the guidance of a physiotherapist.. 15 patients in group 2 were given shamtens treatment to the shoulder area for 25 minutes ( 20 sessions, 5 times a week), then, a classical stroke rehabilitation program was applied under the guidance of a physiotherapist.15 patients in group 3 were given 100 hz ifc treatment to the shoulder area for 25 minutes ( 20 sessions, 5 times a week), then, a classical stroke rehabilitation program was applied under the guidance of a physiotherapist. 15 patients in group 4 were given shamifc treatment to the shoulder area for 25 minutes ( 20 sessions, 5 times a week), then, a classical stroke rehabilitation program was applied under the guidance of a physiotherapist.

Eligibility criteria:
inclusion criteria: 1.having shoulder pain due to hemiplegia 2- having had hemiplegia in the last 8 months 3- having hemiplegia for the first time 4- not having a problem in the painful shoulder before hemiplegia 5- normal light touch and pinprick tests of the affected shoulder 6- pain level in the affected extremity as measured by vas is at least 4 7- brunnstrom upper extremity stage with 1-2-3 exclusion criteria: 1. neoplasia 2. uncontrolled hypertension 3. serious arrhythmias 4. having pacemakers 5. epilepsy 6. severe sensory impairment, wound, infection in the application area 7. bleeding disorders 9. uncooperative patients 10- patients with acute infection 11- patients with a history of trauma to the painful shoulder 12- treatment for pain in the affected shoulder (blockage, intra-articular injection, and physical therapy agent)

Keywords: rehabilitation exercise tens